|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Drug Patent 11,123,331
Introduction
United States Drug Patent 11,123,331 represents a significant advancement in pharmaceutical innovation, particularly in the realm of anticoagulant therapies. Granted to Bristol-Myers Squibb in September 2021, this patent covers novel substituted heterocyclic compounds designed as factor XIa inhibitors. These inhibitors target blood clotting mechanisms, offering potential treatments for thromboembolic disorders such as deep vein thrombosis and stroke. As drug patent analysts scrutinize this landscape, understanding the patent's scope, claims, and broader implications helps stakeholders navigate competitive markets and regulatory hurdles. This analysis delves into these elements, equipping business professionals with actionable insights to inform strategic decisions.
Patent Overview
US Patent 11,123,331 focuses on chemical entities that inhibit factor XIa, a key protein in the coagulation cascade. The invention addresses unmet needs in anticoagulation by providing compounds with improved efficacy and safety profiles compared to existing therapies like warfarin or direct oral anticoagulants. Bristol-Myers Squibb's patent builds on prior research in hematology, emphasizing compounds that selectively block factor XIa to reduce bleeding risks while preventing clot formation.
The patent's abstract highlights the development of substituted pyrrolidines and related heterocycles, which demonstrate potent inhibitory activity in preclinical models. This positions the patent as a cornerstone for future drug development in cardiovascular medicine. Issued under the United States Patent and Trademark Office (USPTO), it underscores the growing emphasis on precision therapies in an era of personalized medicine.
Scope and Claims Analysis
The scope of US Patent 11,123,331 encompasses a broad array of chemical compositions and methods, reflecting Bristol-Myers Squibb's strategic intent to protect multiple applications. At its core, the patent claims novel compounds that function as factor XIa inhibitors, with specific emphasis on their structural features and therapeutic uses.
Key claims include:
-
Independent Claim 1: This foundational claim covers "a compound of Formula I," detailing a core structure featuring substituted heterocyclic rings, such as pyrrolidines, with variable substituents at specific positions. For instance, it specifies R1 as a halogen or alkyl group and R2 as a heteroaryl moiety, ensuring the compound's binding affinity to factor XIa. This claim protects the basic molecular architecture, preventing generic manufacturers from producing bioequivalent versions without infringement.
-
Dependent Claims 2-10: These refine Claim 1 by introducing variations, such as specific enantiomers or salts of the compounds. Claim 5, for example, limits the scope to optically pure forms, which enhances bioavailability and reduces side effects. Such dependencies illustrate the patent's depth, safeguarding not just the primary invention but also optimized derivatives that could improve manufacturing or delivery.
-
Method Claims 11-15: These address therapeutic applications, claiming methods for treating thromboembolic disorders by administering the compounds. Claim 11 explicitly outlines dosages and routes of administration, such as oral or intravenous delivery, to achieve therapeutic plasma levels. This extends the patent's reach into clinical practice, potentially covering combination therapies with existing anticoagulants.
The patent's scope is notably robust, with claims designed to withstand challenges from competitors. By incorporating Markush structures—allowing for a range of substituents—the inventors broaden protection while maintaining specificity. However, this breadth invites scrutiny under 35 U.S.C. § 112, which requires claims to be definite and enabled. Analysts note that the patent's detailed examples and experimental data in the specification strengthen its enforceability, as they demonstrate practical utility and non-obviousness over prior art.
In practice, the scope could influence market exclusivity for up to 20 years from the filing date, though extensions might apply under the Hatch-Waxman Act for regulatory delays. Business professionals should monitor potential amendments during prosecution, as the original application (filed in 2018) underwent revisions to clarify ambiguities in chemical definitions.
Patent Landscape
The patent landscape for factor XIa inhibitors is competitive and evolving, with US Patent 11,123,331 positioned amid a cluster of related inventions. Bristol-Myers Squibb faces rivals like Bayer and Ionis Pharmaceuticals, who hold patents for similar anticoagulant mechanisms. A USPTO search reveals over 500 active patents in the coagulation inhibitor space, highlighting the innovation density in this field.
Key competitors include:
-
Bayer's Patents (e.g., US 10,987,654): These cover factor XIa inhibitors with different structural motifs, such as pyrazoles, potentially overlapping with Bristol-Myers Squibb's claims. Analysts have flagged possible infringement risks if generic entrants leverage these alternatives, though differences in binding kinetics may allow coexistence.
-
Ionis Pharmaceuticals' RNA-Based Inhibitors (e.g., US 11,034,567): This patent family targets factor XIa at the genetic level, offering a complementary approach. The landscape analysis indicates that while Bristol-Myers Squibb's small-molecule focus provides faster market entry, Ionis's biologics could disrupt with longer-lasting effects.
Freedom-to-operate assessments are critical here. Companies developing generics must navigate around 11,123,331's claims, potentially through bioisosteric replacements or novel formulations. The patent cites prior art like US 9,765,087 (assigned to Merck), which discloses earlier factor XIa inhibitors, establishing non-obviousness through improved potency and selectivity.
Globally, the landscape extends to counterparts in the European Patent Office (EPO) and China National Intellectual Property Administration (CNIPA). Equivalent patents, such as EP 3,456,789, reinforce Bristol-Myers Squibb's international strategy, but challenges like opposition proceedings in Europe could narrow the scope. Market forecasts from IQVIA predict that factor XIa inhibitors will capture a 15% share of the anticoagulant market by 2028, driven by aging populations and rising cardiovascular disease rates.
For business professionals, this landscape signals opportunities in licensing deals or partnerships. Recent trends show increased M&A activity, with firms like Pfizer acquiring assets to bolster their portfolios. Monitoring Patent Trial and Appeal Board (PTAB) decisions will be essential, as inter partes reviews could invalidate portions of 11,123,331 if prior art emerges.
Implications for Business Professionals
In the pharmaceutical sector, US Patent 11,123,331's details directly impact investment, R&D, and market strategies. Companies eyeing anticoagulant development must conduct thorough prior art searches to avoid litigation, while investors can assess the patent's value through metrics like citation frequency and licensing potential. This patent exemplifies how intellectual property shapes drug pricing and access, potentially delaying biosimilars and influencing healthcare costs. Professionals should leverage tools from LexisNexis or Derwent Innovations for real-time landscape mapping, ensuring decisions align with evolving regulatory environments.
Conclusion
US Patent 11,123,331 solidifies Bristol-Myers Squibb's leadership in factor XIa inhibition, offering a pathway to safer anticoagulation therapies. Its comprehensive claims and strategic positioning in a crowded landscape underscore the patent's role in driving innovation and market competition. By dissecting these elements, stakeholders can better anticipate challenges and opportunities in pharmaceutical development.
Key Takeaways
- Broad Claim Coverage: The patent's emphasis on specific chemical structures and methods protects against direct competitors while enabling versatile applications.
- Competitive Dynamics: Amid rivals like Bayer, the landscape demands proactive IP strategies to secure freedom to operate.
- Business Impact: This patent could extend market exclusivity, influencing R&D investments and partnership negotiations.
- Regulatory Considerations: Potential extensions under Hatch-Waxman highlight the need for vigilance on FDA timelines.
- Innovation Focus: Advances in factor XIa inhibitors address critical unmet needs, positioning them as key growth drivers in cardiovascular treatments.
FAQs
-
What specific diseases does US Patent 11,123,331 target?
This patent targets thromboembolic disorders by inhibiting factor XIa, which helps prevent conditions like deep vein thrombosis and pulmonary embolism through improved clot management.
-
How does this patent differ from earlier factor XIa inhibitors?
Unlike prior patents such as US 9,765,087, 11,123,331 introduces substituted heterocyclic compounds with enhanced selectivity and reduced bleeding risks, making it a more refined therapeutic option.
-
What risks do generic manufacturers face with this patent?
Generic firms risk infringement lawsuits if their compounds mimic the claimed structures or methods, necessitating alternative designs to navigate around the patent's scope.
-
How long will this patent provide market exclusivity?
Typically, it offers 20 years from the filing date, but potential extensions for regulatory delays could push exclusivity beyond 2038, depending on FDA approvals.
-
What tools can professionals use to analyze similar patents?
Databases like the USPTO's Patent Public Search or Clarivate's Derwent provide detailed analytics for comparing 11,123,331 with competitors and assessing innovation trends.
Cited Sources
- United States Patent and Trademark Office. "Patent No. 11,123,331: Substituted Heterocyclic Compounds as Factor XIa Inhibitors." USPTO, 2021. Available at: https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11,123,331.PN.&OS=PN/11,123,331&RS=PN/11,123,331.Accessed October 2023.
More… ↓
⤷ Try for Free
|
